Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Laura E Niklason is President, CEO and Director at Humacyte. OQRO lists 9 transactions filed with the SEC under this name, the latest on Jun 12, 2026, each linked to the official Form 4.
President, CEO and Director
Disclosures on record
9
Companies involved
1
1 buy, median −19.0 pts vs S&P 500, beat it 0 of 1 time.
Average −19.0 pts vs S&P 500. Each buy is one disclosure of open-market purchases in one company on one filing date, filed Nov 21, 2024 to Nov 21, 2024, measured from the first close after the filing. Past results, not a forecast.
1 purchase disclosed; 0% of the 1 measured at 90 days finished ahead of the index.
Not ranked: fewer than 10 purchases measured at 90 days. The middle of the 82 ranked insiders is −5.5 pts (median, against the S&P 500).
HumacyteHUMA
9 disclosures · Nov 2024 – Jun 2026 · 6 sold · 1 bought
Jun 11, 202680Kdisclosed Jun 12
DetailsOfficial recordNov 16, 2025311Kdisclosed Nov 17
DetailsOfficial recordEqual weight counts every purchase once; by size counts it for its disclosed dollars. Both are measured from the first close after it was reported. Past results describe the past, not a forecast. How this is measured · Leaderboard
Aug 19, 2025Sold~$1.79Mdisclosed Aug 20
DetailsOfficial recordAug 18, 2025Sold~$1.01Mdisclosed Aug 20
DetailsOfficial recordAug 20, 2025Sold~$935K
DetailsOfficial recordNov 19, 2024Bought~$8Kdisclosed Nov 21
DetailsOfficial recordNov 18, 2024Sold~$3.6Mdisclosed Nov 21
DetailsOfficial recordNov 19, 2024Sold~$1.86Mdisclosed Nov 21
DetailsOfficial recordNov 20, 2024Sold~$1.15Mdisclosed Nov 21
DetailsOfficial recordAs of the latest filing on , Laura E Niklason reported holding 243,851 shares of Humacyte (HUMA), worth about $136K at the last close of $1 (Nov 13, 2026).
Humacyte's proxy statement reports total compensation of $5.23M for Laura E Niklason for fiscal year 2025. The total is the one in the Summary Compensation Table: it counts stock awards at their value on the grant date, so it is not the cash received. Proxy statement filed Apr 28, 2026
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Humacyte HUMA | 243,851 | 244K direct | $1 | $136K | Nov 19, 2024 |
Is this Laura E Niklason’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Laura E Niklason bought shares on the open market in 2021, 2022 and 2024, and has not bought since 2024. Sales in each of the last 5 years.
Laura E Niklason reported 8 open-market purchases and 34 sales since 2021; purchases in 3 different years, most recently 2024.
| Year | Bought | Sold |
|---|---|---|
| 2025 | — | $3.73M3×3 trades |
| 2024 | $46K4×4 trades | $27M15×15 trades |
| 2023 | — | $33.4M7×7 trades |
| 2022 | $82K3×3 trades | $8.64M5×5 trades |
| 2021 | $15.2M1×1 trade | $2.73M4×4 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated Nov 19, 2024, Laura E Niklason reported holding 243,851 shares of Humacyte (HUMA). At the last close of $1 on Nov 13, 2026, that is about $136K. This is the stake disclosed in filings, not a net worth.
Humacyte's proxy statement reports total compensation of $5.23M for Laura E Niklason for fiscal year 2025. The total is the one in the Summary Compensation Table: it counts stock awards at their value on the grant date, so it is not the cash received.
Laura E Niklason bought shares on the open market in 2021, 2022 and 2024, and has not bought since 2024. Sales in each of the last 5 years.
In SEC filings since 2021: the latest open-market purchase is from 2024; the latest open-market sale is from 2025.
Humacyte (HUMA), from 2021 to 2025: 8 purchases and 34 sales.
Laura E Niklason reported 8 open-market purchases and 34 sales here, 2021 to 2025.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.